Study record

MOTS-c: A potential anti-pulmonary fibrosis factor derived by mitochondria

Zhang Z, Chen D, Du K et al. · Mitochondrion · 2023

ReviewSeveralEvidence tier R
PubMed 37307934doi:10.1016/j.mito.2023.06.002Compare with another study

What this study reported

Reviewed reported effects of MOTS-c on glucose and lipid metabolism, cellular and mitochondrial homeostasis and systemic inflammatory responses, and its description as a candidate exercise mimetic. Summarised proposed links between MOTS-c expression changes, ageing and the pathogenesis of pulmonary fibrosis, and identified candidate targets for future study.

Limitations

Narrative review with no stated search strategy or appraisal of included studies; the link to pulmonary fibrosis is largely extrapolated from indirect evidence rather than from direct studies in that disease.

Study record

Annotated fields for this study
Study modelReview
Substance studiedSeveralMore than one of these is central to the paper (common for reviews).
SpeciesNot reported
System studiedPublished literature on MOTS-c, mitochondrial dysfunction, ageing and pulmonary fibrosis
PopulationNot reported
DesignNarrative review
Sample size as reportedNot reported
Control groupNot reported
Route (data field only)Not reported
Endpoints measuredglucose and lipid metabolism; mitochondrial and cellular homeostasis; systemic inflammatory responses; ageing-related changes in MOTS-c expression
Pathways measuredAMPK signalling · Inflammation · Lipid metabolism · Oxidative stress
Research areasLung · Aging · Mitochondrial biology
Evidence tierR — Review (context, not evidence)
Publication typesJournal Article, Review, Research Support, Non-U.S. Gov't

Appraisal

Each dimension is recorded separately and never combined into a single score. A study can be well controlled and still tell you little about people.

Relevance to MOTS-c
Direct
Model applicability
n/a
Sample size
n/a
Controls
n/a
Outcome validity
n/a
Support for its own conclusion
Weak

Provenance

  • Bibliographic fields retrieved from PubMed E-utilities efetch (title, journal, date, authors, DOI) on 2026-11-11.
  • Annotated from the published abstract.
  • Editorial review: approved (2026-11-11).
  • Classification follows the site methodology; the record describes the study, not what MOTS-c does in people.